Advertisement

AIDS and Behavior

, Volume 19, Issue 4, pp 626–634 | Cite as

Comprehensive Evaluation of Caregiver-Reported Antiretroviral Therapy Adherence for HIV-Infected Children

  • Rachel C. VreemanEmail author
  • Winstone M. Nyandiko
  • Hai Liu
  • Wanzhu Tu
  • Michael L. Scanlon
  • James E. Slaven
  • Samuel O. Ayaya
  • Thomas S. Inui
Original Paper

Abstract

For HIV-infected children, adherence to antiretroviral therapy (ART) is often assessed by caregiver report but there are few data on their validity. We conducted prospective evaluations with 191 children ages 0–14 years and their caregivers over 6 months in western Kenya to identify questionnaire items that best predicted adherence to ART. Medication Event Monitoring Systems® (MEMS, MWV/AARDEX Ltd., Switzerland) electronic dose monitors were used as external criterion for adherence. We employed a novel variable selection tool using the LASSO technique with logistic regression to identify items best correlated with dichotomized MEMS adherence (≥90 or <90 % doses taken). Nine of 48 adherence items were identified as the best predictors of adherence, including missed or late doses in the past 7 days, problems giving the child medicines, and caregiver-level factors like not being present at medication taking. These items could be included in adherence assessment tools for pediatric patients.

Keywords

Pediatric HIV care Adherence Best practice Resource-limited setting 

Notes

Acknowledgments

We would first and foremost like to thank the Kenyan families who took part in this study. We would also like to acknowledge the significant work of key clinicians and nurses at AMPATH in promoting and helping evaluate adherence, including Irene Marete, Edith Apondi, Peter Gisore, Constance Tenge, Esther Nabakwe, John Chumba, Lucy Warui, Mary Rugut, Victor Cheboi, and Christine Mukhwana. This research was supported in part by a Grant (1K23MH087225) to Dr. Vreeman from the NIMH and AMPATH Plus with support from the United States Agency for International Development as part of the President’s Emergency Plan for AIDS Relief (PEPFAR).

Conflict of interest

The authors have no conflicts of interest to disclose.

Supplementary material

10461_2015_998_MOESM1_ESM.docx (188 kb)
Appendix 1 (DOCX 188 kb)

References

  1. 1.
    World Health Organization. Global HIV/AIDS response: epidemic update and health sector progress towards universal access—progress report 2011. Geneva: World Health Organization; 2011.Google Scholar
  2. 2.
    Doerholt K, Duong T, Tookey P, et al. Outcomes for human immunodeficiency virus-1-infected infants in the United kingdom and Republic of Ireland in the era of effective antiretroviral therapy. Pediatr Infect Dis J. 2006;25(5):420–6.CrossRefPubMedGoogle Scholar
  3. 3.
    Gibb DM, Duong T, Tookey PA, et al. Decline in mortality, AIDS, and hospital admissions in perinatally HIV-1 infected children in the United Kingdom and Ireland. BMJ (Clin Res ed). 2003;327(7422):1019.CrossRefGoogle Scholar
  4. 4.
    Gibb DM, Goodall RL, Giacomet V, McGee L, Compagnucci A, Lyall H. Adherence to prescribed antiretroviral therapy in human immunodeficiency virus-infected children in the PENTA 5 trial. Pediatr Infect Dis J. 2003;22(1):56–62.CrossRefPubMedGoogle Scholar
  5. 5.
    Hogg RS, Heath KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA. 1998;279(6):450–4.CrossRefPubMedGoogle Scholar
  6. 6.
    Needham DM, Hogg RS, Yip B, O’Shaughnessy M, Schechter MT, Montaner JS. The impact of antiretroviral therapy on AIDS survival observed in a province-wide drug treatment programme. Int J STD AIDS. 1998;9(6):370–2.PubMedGoogle Scholar
  7. 7.
    Bangsberg DR, Kroetz DL, Deeks SG. Adherence-resistance relationships to combination HIV antiretroviral therapy. Curr HIV/AIDS Rep. 2007;4(2):65–72.CrossRefPubMedGoogle Scholar
  8. 8.
    Gavin PJ, Yogev R. The role of protease inhibitor therapy in children with HIV infection. Paediatr Drugs. 2002;4(9):581–607.CrossRefPubMedGoogle Scholar
  9. 9.
    Mullen J, Leech S, O’Shea S, et al. Antiretroviral drug resistance among HIV-1 infected children failing treatment. J Med Virol. 2002;68(3):299–304.CrossRefPubMedGoogle Scholar
  10. 10.
    San-Andres FJ, Rubio R, Castilla J, et al. Incidence of acquired immunodeficiency syndrome-associated opportunistic diseases and the effect of treatment on a cohort of 1115 patients infected with human immunodeficiency virus, 1989–1997. Clin Infect Dis. 2003;36(9):1177–85.CrossRefPubMedGoogle Scholar
  11. 11.
    Tam LW, Chui CK, Brumme CJ, et al. The relationship between resistance and adherence in drug-naive individuals initiating HAART is specific to individual drug classes. J Acquir Immune Defic Syndr. 2008;49(3):266–71.CrossRefPubMedCentralPubMedGoogle Scholar
  12. 12.
    Chesney MA. The elusive gold standard. Future perspectives for HIV adherence assessment and intervention. J Acquir Immune Defic Syndr. 2006;43(Suppl 1):S149–55.CrossRefPubMedGoogle Scholar
  13. 13.
    Simoni JM, Kurth AE, Pearson CR, Pantalone DW, Merrill JO, Frick PA. Self-report measures of antiretroviral therapy adherence: a review with recommendations for HIV research and clinical management. AIDS Behav. 2006;10(3):227–45.CrossRefPubMedCentralPubMedGoogle Scholar
  14. 14.
    Vreeman RC, Nyandiko WM, Blaschke TF. Adherence to antiretroviral therapy for adults and children in resource-limited settings. Rev Antivir Ther. 2009;2(Suppl):S6–13.Google Scholar
  15. 15.
    Simoni JM, Montgomery A, Martin E, New M, Demas PA, Rana S. Adherence to antiretroviral therapy for pediatric HIV infection: a qualitative systematic review with recommendations for research and clinical management. Pediatrics. 2007;119(6):e1371–83.CrossRefPubMedGoogle Scholar
  16. 16.
    Allison SM, Koenig LJ, Marhefka SL, et al. Assessing medication adherence of perinatally HIV-infected children using caregiver interviews. J Assoc Nurses AIDS Care. 2010;21(6):478–88.CrossRefPubMedCentralPubMedGoogle Scholar
  17. 17.
    Farley J, Hines S, Musk A, Ferrus S, Tepper V. Assessment of adherence to antiviral therapy in HIV-infected children using the Medication Event Monitoring System, pharmacy refill, provider assessment, caregiver self-report, and appointment keeping. J Acquir Immune Defic Syndr. 2003;33(2):211–8.CrossRefPubMedGoogle Scholar
  18. 18.
    Van Dyke RB, Lee S, Johnson GM, et al. Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection. Pediatrics. 2002;109(4):e61.CrossRefPubMedGoogle Scholar
  19. 19.
    Haberer JE, Cook A, Walker AS, et al. Excellent adherence to antiretrovirals in HIV+Zambian children is compromised by disrupted routine, HIV nondisclosure, and paradoxical income effects. PLoS ONE. 2011;6(4):e18505.CrossRefPubMedCentralPubMedGoogle Scholar
  20. 20.
    Davies MA, Boulle A, Fakir T, Nuttall J, Eley B. Adherence to antiretroviral therapy in young children in Cape Town, South Africa, measured by medication return and caregiver self-report: a prospective cohort study. BMC Pediatr. 2008;8:34.CrossRefPubMedCentralPubMedGoogle Scholar
  21. 21.
    Vreeman RC, Wiehe SE, Pearce EC, Nyandiko WM. A systematic review of pediatric adherence to antiretroviral therapy in low- and middle-income countries. Pediatr Infect Dis J. 2008;27(8):686–91.CrossRefPubMedGoogle Scholar
  22. 22.
    Arnsten JH, Demas PA, Farzadegan H, et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. Clin Infect Dis. 2001;33(8):1417–23.CrossRefPubMedCentralPubMedGoogle Scholar
  23. 23.
    Deschamps AE, De Geest S, Vandamme AM, Bobbaers H, Peetermans WE, Van Wijngaerden E. Diagnostic value of different adherence measures using electronic monitoring and virologic failure as reference standards. AIDS Patient Care STDS. 2008;22(9):735–43.CrossRefPubMedGoogle Scholar
  24. 24.
    Thompson MA, Mugavero MJ, Amico KR, et al. Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel. Ann Intern Med. 2012;156(11):817–33.CrossRefPubMedCentralPubMedGoogle Scholar
  25. 25.
    Muller AD, Jaspan HB, Myer L, et al. Standard measures are inadequate to monitor pediatric adherence in a resource-limited setting. AIDS Behav. 2011;15(2):422–31.CrossRefPubMedCentralPubMedGoogle Scholar
  26. 26.
    Boyd MA, Cooper DA. Second-line combination antiretroviral therapy in resource-limited settings: facing the challenges through clinical research. AIDS. 2007;21(Suppl 4):S55–63.CrossRefPubMedGoogle Scholar
  27. 27.
    Vreeman RC, Nyandiko WM, Ayaya SO, Walumbe EG, Marrero DG, Inui TS. Factors sustaining pediatric adherence to antiretroviral therapy in western Kenya. Qual Health Res. 2009;19(12):1716–29.CrossRefPubMedGoogle Scholar
  28. 28.
    Vreeman RC, Nyandiko WM, Ayaya SO, Walumbe EG, Inui TS. Cognitive interviewing for cross-cultural adaptation of pediatric antiretroviral therapy adherence measurement items. Int J Behav Med. 2014;21:186–96.CrossRefPubMedGoogle Scholar
  29. 29.
    Einterz RM, Kimaiyo S, Mengech HN, et al. Responding to the HIV pandemic: the power of an academic medical partnership. Acad Med. 2007;82(8):812–8.CrossRefPubMedGoogle Scholar
  30. 30.
    Inui TS, Nyandiko WM, Kimaiyo SN, et al. AMPATH: living proof that no one has to die from HIV. J Gen Int Med. 2007;22(12):1745–50.CrossRefGoogle Scholar
  31. 31.
    Tibshirani R. Regression shrinkage and selection via the LASSO. J R Stat Soc Ser B. 1996;58(1):267–88.Google Scholar
  32. 32.
    Meier L, Van De Geer S, Buhlmann P. The group LASSO for logistic regression. J R Stat Soc Ser B. 2008;70(1):53–71.CrossRefGoogle Scholar
  33. 33.
    Bangsberg D, Hecht FM, Charlebois ED, Chesney M, Moss A. Comparing objective measures of adherence to HIV antiretroviral therapy: electronic medication monitors and unannounced pill counts. AIDS Behav. 2001;5(3):275–81.CrossRefGoogle Scholar
  34. 34.
    Haberer JE, Kiwanuka J, Nansera D, Ragland K, Mellins C, Bangsberg DR. Multiple measures reveal antiretroviral adherence successes and challenges in HIV-infected Ugandan children. PLoS ONE. 2012;7(5):e36737.CrossRefPubMedCentralPubMedGoogle Scholar
  35. 35.
    Bangsberg DR, Moss AR, Deeks SG. Paradoxes of adherence and drug resistance to HIV antiretroviral therapy. J Antimicrob Chemother. 2004;53(5):696–9.CrossRefPubMedGoogle Scholar
  36. 36.
    Sethi AK, Celentano DD, Gange SJ, Moore RD, Gallant JE. Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis. 2003;37(8):1112–8.CrossRefPubMedGoogle Scholar
  37. 37.
    Bangsberg DR. Less than 95 % adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis. 2006;43(7):939–41.CrossRefPubMedGoogle Scholar
  38. 38.
    Wilson IB, Bangsberg DR, Shen J, et al. Heterogeneity among studies in rates of decline of antiretroviral therapy adherence over time: results from the multisite adherence collaboration on HIV 14 study. J Acquir Immune Defic Syndr. 2013;64(5):448–54.CrossRefPubMedCentralPubMedGoogle Scholar
  39. 39.
    WHO. WHO Global Database on Child Growth and Malnutrition. Geneva: World Health Organization; 1997.Google Scholar
  40. 40.
    Marhefka SL, Farley JJ, Rodrigue JR, Sandrik LL, Sleasman JW, Tepper VJ. Clinical assessment of medication adherence among HIV-infected children: examination of the Treatment Interview Protocol (TIP). AIDS Care. 2004;16(3):323–38.CrossRefPubMedGoogle Scholar
  41. 41.
    Katko E, Johnson GM, Fowler SL, Turner RB. Assessment of adherence with medications in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 2001;20(12):1174–6.CrossRefPubMedGoogle Scholar
  42. 42.
    Scanlon ML, Vreeman RC. Current strategies for improving access and adherence to antiretroviral therapies in resource-limited settings. HIV/AIDS Res Palliat Care. 2013;5:1–17.Google Scholar
  43. 43.
    Berg KM, Arnsten JH. Practical and conceptual challenges in measuring antiretroviral adherence. J Acquir Immune Defic Syndr. 2006;43(Suppl 1):S79–87.CrossRefPubMedCentralPubMedGoogle Scholar
  44. 44.
    Bova CA, Fennie KP, Knafl GJ, Dieckhaus KD, Watrous E, Williams AB. Use of electronic monitoring devices to measure antiretroviral adherence: practical considerations. AIDS Behav. 2005;9(1):103–10.CrossRefPubMedGoogle Scholar
  45. 45.
    Muller AD, Bode S, Myer L, Roux P, von Steinbuchel N. Electronic measurement of adherence to pediatric antiretroviral therapy in South Africa. Pediatr Infect Dis J. 2008;27(3):257–62.CrossRefPubMedGoogle Scholar
  46. 46.
    Wendel CS, Mohler MJ, Kroesen K, Ampel NM, Gifford AL, Coons SJ. Barriers to use of electronic adherence monitoring in an HIV clinic. Ann Pharmacother. 2001;35(9):1010–5.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Rachel C. Vreeman
    • 1
    • 2
    • 3
    Email author
  • Winstone M. Nyandiko
    • 2
    • 4
  • Hai Liu
    • 5
  • Wanzhu Tu
    • 5
  • Michael L. Scanlon
    • 1
    • 2
  • James E. Slaven
    • 5
  • Samuel O. Ayaya
    • 2
    • 4
  • Thomas S. Inui
    • 2
    • 3
    • 6
  1. 1.Children’s Health Services Research, Department of PediatricsIndiana University School of MedicineIndianapolisUSA
  2. 2.Academic Model Providing Access to Healthcare (AMPATH)EldoretKenya
  3. 3.Regenstrief Institute, Inc.IndianapolisUSA
  4. 4.Department of Child Health and PaediatricsMoi University School of MedicineEldoretKenya
  5. 5.Department of BiostatisticsIndiana University School of MedicineIndianapolisUSA
  6. 6.Department of MedicineIndiana University School of MedicineIndianapolisUSA

Personalised recommendations